Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
EMPEROR-Reduced trial committees and investigators
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial'. Together they form a unique fingerprint.